H.C. Wainwright analyst Andres Maldonado reiterated a Buy rating and $40.00 price target on Syndax Pharmaceuticals (NASDAQ: SNDX).

The analyst commented: "Syndax’s oral presentation at ASCO 2026 addresses key investor questions regarding the credibility of Revuforj in the transplant maintenance setting. In our view, the data reinforce the company’s central message that Revuforj is broadly deployable across a continuum of treatment and patient settings in AML. The granular patient details highlight Revuforj’s efficacy and durability in a biologically diverse set of patients and underscores the thesis that Revuforj targets a core leukemogenic transcriptional program shared by multiple AML genotypes. The patient population included a mix of heavily pretreated adult (N=13) and pediatric (N=11) patients who underwent mixed types of HSCT, conditioning regimens, and GVHD prophylaxis strategies. 71% of patients (17/24) had KMT2Ar, 25% (6/24) had NPM1m, and 4% (1/24) had NUP98r AML genotypes. Among all patients, the median time to initiate revumenib post-HSCT was 82 days (range: 42 – 174 days) and median duration of Revuforj therapy post-HSCT was 10 months (range: 0.5-36 months) with 29% of patients (7/24) still remaining on Revuforj at last follow-up. mOS and EFS from the time of HSCT were not reached, and the 2-year OS rate was 90% in the overall population. In contrast, a historical cohort of patients with the same genetic mutations had a 2 year OS of 51%. We reiterate our Buy rating and $40 PT."

For an analyst ratings summary and ratings history on Syndax Pharmaceuticals click here. For more ratings news on Syndax Pharmaceuticals click here.

Shares of Syndax Pharmaceuticals closed at $18.39 yesterday.